Carlsmed Inc’s recently made public that its 10% Owner B CAPITAL GROUP MANAGEMENT, L. acquired Company’s shares for reported $20.0 million on Jul 24 ’25. In the deal valued at $15.00 per share,1,333,333 shares were bought. As a result of this transaction, B CAPITAL GROUP MANAGEMENT, L. now holds 5,013,839 shares worth roughly $66.68 million.
Then, Sidow Kevin bought 13,333 shares, generating $199,995 in total proceeds. Upon buying the shares at $15.00, the Director now owns 59,566 shares.
Before that, Mittendorff Robert II bought 1,333,333 shares. Carlsmed Inc shares valued at $19,999,995 were divested by the Director at a price of $15.00 per share. As a result of the transaction, Mittendorff Robert II now holds 5,013,839 shares, worth roughly $66.68 million.
Truist initiated its Carlsmed Inc [CARL] rating to a Buy in a research note published on August 18, 2025; the price target was $18. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in mid August with a ‘”an Overweight”‘ rating. Goldman began covering CARL with “Buy” recommendation on August 18, 2025. BTIG Research started covering the stock on August 18, 2025. It rated CARL as “a Buy”.
Price Performance Review of CARL
On Friday, Carlsmed Inc [NASDAQ:CARL] saw its stock fall -2.85% to $13.3. Over the last five days, the stock has gained 1.99%. Nevertheless, the stocks have fallen -8.28% over the past one year.
Levels Of Support And Resistance For CARL Stock
The 24-hour chart illustrates a support level at 12.42, which if violated will result in even more drops to 11.55. On the upside, there is a resistance level at 13.91. A further resistance level may holdings at 14.53.
The most recent change occurred on August 18, 2025 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
